<p>，/PRNewswire/ -- Levi &amp; Korsinsky, LLP 通知 <strong>PepGen Inc.</strong>（&#34;PepGen Inc.&#34; 或 &#34;公司&#34;）（NASDAQ: PEPG）的投资者有关一起集体诉讼证券案件。</p>
<p><strong>案件定义：</strong> 本诉讼旨在为在 2024 年 3 月 7 日至 2025 年 3 月 3 日期间受到涉嫌证券欺诈影响的 PepGen Inc. 投资者追回损失。请点击以下链接获取更多信息并与我们团队的成员联系：</p>
<p>https://zlk.com/pslra-1/pepgen-inc-lawsuit-submission-form?prid=160189&amp;wire=4</p>
<p><strong>PEPG</strong> 投资者也可以通过电子邮件联系 Joseph E. Levi, Esq.，邮箱为 [email protected]，或拨打电话 (212) 363-7500。</p>
<p><strong>案件详情：</strong> 提起的投诉指控被告作出了虚假陈述和/或隐瞒了以下事实：(i) 公司的主要产品候选药物 PGN-EDO51 的有效性和安全性低于被告所让投资者相信的水平；(ii) 第二阶段 CONNECT2 研究在美国食品和药物管理局（&#34;FDA&#34;）批准方面存在危险或其他缺陷；(iii) 由于上述所有原因，PepGen 可能会停止 CONNECT2 研究，PGN-EDO51 的临床、监管和商业前景被夸大；(iv) 因此，被告的公开声明在所有相关时间都是实质性虚假和误导的。</p>
<p><strong>接下来会发生什么？</strong> 如果您在相关时间段内在 PepGen Inc. 中遭受损失，您有直到 <strong>2025 年 8 月 8 日</strong> 的时间请求法院任命您为首席原告。您分享任何赔偿的能力并不要求您担任首席原告。</p>
<p><strong>对您没有费用：</strong> 如果您是集体成员，您可能有权在不支付任何自付费用或费用的情况下获得赔偿。<strong>参与没有费用或义务。</strong></p>
<p><strong>为什么选择 Levi &amp; Korsinsky：</strong> 在过去的 20 年里，Levi &amp; Korsinsky 的团队为受害股东争取了数亿美元，并建立了赢得高风险案件的良好记录。我们的公司在复杂证券诉讼中代表投资者方面拥有丰富的专业知识，并拥有超过 70 名员工为我们的客户服务。连续七年，Levi &amp; Korsinsky 在 ISS Securities Class Action Services 的前 50 名报告中被评为美国顶级证券诉讼公司之一。</p>
<p><strong>联系方式：</strong></p>
<p>Levi &amp; Korsinsky, LLP</p>
<p>Joseph E. Levi, Esq.</p>
<p>Ed Korsinsky, Esq.</p>
<p>33 Whitehall Street, 17th Floor</p>
<p>New York, NY 10004</p>
<p>[email protected]</p>
<p>电话: (212) 363-7500</p>
<p>传真: (212) 363-7171</p>
<p>www.zlk.com</p>
<p>来源 Levi &amp; Korsinsky, LLP</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwODA4Jk5ld3NJdGVtSWQ9Tlk0Njk5MiZUcmFuc21pc3Npb25fSWQ9MjAyNTA4MDgwODQ1UFJfTkVXU19VU1BSX19fX19OWTQ2OTky?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwODA4Jk5ld3NJdGVtSWQ9Tlk0Njk5MiZUcmFuc21pc3Npb25fSWQ9MjAyNTA4MDgwODQ1UFJfTkVXU19VU1BSX19fX19OWTQ2OTky"/></p>

PEPG

<p>Levi & Korsinsky, LLP 宣布对 PepGen Inc.（纳斯达克代码：PEPG）提起集体诉讼，指控其在 2024 年 3 月 7 日至 2025 年 3 月 3 日期间对投资者进行证券欺诈。诉讼称，该公司对其主要产品候选者 PGN-EDO51 的有效性和安全性进行了虚假陈述，并且 CONNECT2 研究在 FDA 批准方面存在缺陷。投资者可以在 2025 年 8 月 8 日之前申请成为主原告，参与诉讼无需支付费用</p>

<p>, /PRNewswire/ -- Levi &amp; Korsinsky, LLP notifies investors in <strong>PepGen Inc.</strong> (&#34;PepGen Inc.&#34; or the &#34;Company&#34;) (NASDAQ: PEPG) of a class action securities lawsuit.</p>
<div class="lb-trans"><p>，/PRNewswire/ -- Levi &amp; Korsinsky, LLP 通知 <strong>PepGen Inc.</strong>（&#34;PepGen Inc.&#34; 或 &#34;公司&#34;）（NASDAQ: PEPG）的投资者有关一起集体诉讼证券案件。</p>
</div><p><strong>CLASS DEFINITION:</strong> The lawsuit seeks to recover losses on behalf of PepGen Inc. investors who were adversely affected by alleged securities fraud between March 7, 2024 and March 3, 2025. Follow the link below to get more information and be contacted by a member of our team:</p>
<div class="lb-trans"><p><strong>案件定义：</strong> 本诉讼旨在为在 2024 年 3 月 7 日至 2025 年 3 月 3 日期间受到涉嫌证券欺诈影响的 PepGen Inc. 投资者追回损失。请点击以下链接获取更多信息并与我们团队的成员联系：</p>
</div><p>https://zlk.com/pslra-1/pepgen-inc-lawsuit-submission-form?prid=160189&amp;wire=4</p>
<div class="lb-trans"><p>https://zlk.com/pslra-1/pepgen-inc-lawsuit-submission-form?prid=160189&amp;wire=4</p>
</div><p><strong>PEPG</strong> investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.</p>
<div class="lb-trans"><p><strong>PEPG</strong> 投资者也可以通过电子邮件联系 Joseph E. Levi, Esq.，邮箱为 [email protected]，或拨打电话 (212) 363-7500。</p>
</div><p><strong>CASE DETAILS:</strong> The filed complaint alleges that defendants made false statements and/or concealed that: (i) the Company's lead product candidate, PGN-EDO51, was less effective and safe than defendants had led investors to believe; (ii) phase two, CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration (&#34;FDA&#34;) approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51's clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, defendants' public statements were materially false and misleading at all relevant times.</p>
<div class="lb-trans"><p><strong>案件详情：</strong> 提起的投诉指控被告作出了虚假陈述和/或隐瞒了以下事实：(i) 公司的主要产品候选药物 PGN-EDO51 的有效性和安全性低于被告所让投资者相信的水平；(ii) 第二阶段 CONNECT2 研究在美国食品和药物管理局（&#34;FDA&#34;）批准方面存在危险或其他缺陷；(iii) 由于上述所有原因，PepGen 可能会停止 CONNECT2 研究，PGN-EDO51 的临床、监管和商业前景被夸大；(iv) 因此，被告的公开声明在所有相关时间都是实质性虚假和误导的。</p>
</div><p><strong>WHAT'S NEXT?</strong> If you suffered a loss in PepGen Inc. during the relevant time frame, you have until <strong>August 8, 2025</strong> to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.</p>
<div class="lb-trans"><p><strong>接下来会发生什么？</strong> 如果您在相关时间段内在 PepGen Inc. 中遭受损失，您有直到 <strong>2025 年 8 月 8 日</strong> 的时间请求法院任命您为首席原告。您分享任何赔偿的能力并不要求您担任首席原告。</p>
</div><p><strong>NO COST TO YOU:</strong> If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. <strong>There is no cost or obligation to participate.</strong></p>
<div class="lb-trans"><p><strong>对您没有费用：</strong> 如果您是集体成员，您可能有权在不支付任何自付费用或费用的情况下获得赔偿。<strong>参与没有费用或义务。</strong></p>
</div><p><strong>WHY LEVI &amp; KORSINSKY:</strong> Over the past 20 years, the team at Levi &amp; Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi &amp; Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.</p>
<div class="lb-trans"><p><strong>为什么选择 Levi &amp; Korsinsky：</strong> 在过去的 20 年里，Levi &amp; Korsinsky 的团队为受害股东争取了数亿美元，并建立了赢得高风险案件的良好记录。我们的公司在复杂证券诉讼中代表投资者方面拥有丰富的专业知识，并拥有超过 70 名员工为我们的客户服务。连续七年，Levi &amp; Korsinsky 在 ISS Securities Class Action Services 的前 50 名报告中被评为美国顶级证券诉讼公司之一。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p>Levi &amp; Korsinsky, LLP</p>
</div><p>Joseph E. Levi, Esq.</p>
<div class="lb-trans"><p>Joseph E. Levi, Esq.</p>
</div><p>Ed Korsinsky, Esq.</p>
<div class="lb-trans"><p>Ed Korsinsky, Esq.</p>
</div><p>33 Whitehall Street, 17th Floor</p>
<div class="lb-trans"><p>33 Whitehall Street, 17th Floor</p>
</div><p>New York, NY 10004</p>
<div class="lb-trans"><p>New York, NY 10004</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>Tel: (212) 363-7500</p>
<div class="lb-trans"><p>电话: (212) 363-7500</p>
</div><p>Fax: (212) 363-7171</p>
<div class="lb-trans"><p>传真: (212) 363-7171</p>
</div><p>www.zlk.com</p>
<div class="lb-trans"><p>www.zlk.com</p>
</div><p>SOURCE Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p>来源 Levi &amp; Korsinsky, LLP</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwODA4Jk5ld3NJdGVtSWQ9Tlk0Njk5MiZUcmFuc21pc3Npb25fSWQ9MjAyNTA4MDgwODQ1UFJfTkVXU19VU1BSX19fX19OWTQ2OTky" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=NY46992&amp;Transmission_Id=202508080845PR_NEWS_USPR_____NY46992&amp;DateId=20250808"/></p>

08:45 ET
			
			
				PepGen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 8, 2025 to Discuss Your Rights - PEPG

PepGen Inc.证券欺诈集体诉讼正在进行中：请在2025年8月8日之前联系 Levi & Korsinsky 以讨论您的权利 - PEPG